Not Yet Recruiting PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT06746961

Efficacy and Safety of QL1706 Plus Lenvatinib As 2nd Line Theapy in Patients with Metastatic Esophageal Carcinoma After Disease Progression on ICIs Therapy

A Single-arm, Open-label, Multicenter Phase Ⅰb/Ⅱ Clinical Study of QL1706 (bispecific Antibody Targeting PD-1 and CLTA-4) in Combination with Lenvatinib in Second-line Therapy for Advanced Esophageal Squamous Cell Carcinoma After Disease Progression on Immune Checkpoint Blockades Therapy

Sponsor: The First Affiliated Hospital of Zhengzhou University

Conditions Esophageal Squamous Cell Carcinoma (ESCC)

Interventions Lenvatinib QL1706 (bispecific antibody targeting PD-1 and CLTA-4)

Updated 1 time since 2025 Last updated: Dec 19, 2024 Started: Jan 31, 2025 Primary completion: Jul 31, 2026 Completion: Aug 31, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Esophageal Squamous Cell Carcinoma (ESCC) and is currently actively recruiting participants. The First Affiliated Hospital of Zhengzhou University leads this study, which shows 1 recorded version since 2025 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

1 version recorded

Not Yet Recruiting — PHASE1/PHASE2 [monthly]

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

The First Affiliated Hospital of Zhengzhou University

Data source: The First Affiliated Hospital of Zhengzhou University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.